Bumetanide has anxiolytic effects in rat models of conditioned fear. As a loop diuretic, bumetanide blocks cation-chloride cotransport and this property may allow bumetanide to act as an anxiolytic by modulating GABAergic synaptic transmission in the CNS. Its potential for the treatment of anxiety disorders deserves further investigation. In this study, we evaluated the possible involvement of the basolateral nucleus of the amygdala in the anxiolytic effect of bumetanide.
Introduction
Cation-chloride co-transporters (CCCs) are transmembrane proteins that mediate transport of chloride ions across the cell membrane (Blaesse et al., 2009; Ko et al., 2014) . There are two main types of CCCs, in which chloride is cotransported with sodium ions and/or potassium ions. They can be discriminated by their sensitivity to CCC inhibitors, transported ion stoichiometry and phylogeny (Payne and Forbush, 1995; Isenring and Forbush, 2001; Hannaert et al., 2002) . Members of the sodium-coupled branch, which consists of the Na-K-Cl co-transporters, NKCC1 and NKCC2, move chloride ions into the cell and raise the intracellular concentration of chloride ([Cl À ] i ) above the electrochemical equilibrium for chloride. The potassium-coupled branch, which is composed of four different K-Cl co-transporters (KCC1, KCC2, KCC3 and KCC4), primarily transport chloride ions out of the cell, reducing the [Cl À ] i below the electrochemical equilibrium of chloride (Mount et al., 1998; Staley, 2008, 2012; Dzhala et al., 2010) . In adult neurons, [Cl À ] i is lower than extracellular chloride level, and the reversal potential for chloride currents is near the resting membrane potential of the neurons. Even slight changes in [Cl À ] i can significantly alter the magnitude, and even polarity, of the GABA-mediated chloride current (Fiumelli and Woodin, 2007; Staley, 2008, 2012; Ko et al., 2014) . Anxiolytics such as the benzodiazepines modulate GABAergic neurotransmission. Therefore, loop diuretics including furosemide and bumetanide are thought to have anxiolytic effects and have been tested in rodent models of both cue and contextual fear conditioning (Krystal et al., 2012) . The results showed that bumetanide significantly attenuated both types of conditioned fear, but the detailed mechanism(s) were not elucidated.
There is a considerable amount of evidence suggesting that the basolateral nucleus of the amygdala (BLA) is crucially involved in models of conditioned fear (LeDoux et al., 1990; Kim et al., 1991; Campeau and Davis, 1995; Fanselow and LeDoux, 1999; Maren, 1999) . Either neurotoxic lesions or intracranial injection of glutamate NMDA receptor antagonists into the BLA blocked the acquisition and expression of conditioned fear (Miserendino et al., 1990; Kim et al., 1991; Maren et al., 1996; Gewirtz and Davis, 1997; Walker et al., 2002; Yang and Lu, 2005) . The function of the BLA is thought to underlie the neuroplasticity process, which pairs the conditioned stimulus (CS) and unconditioned stimulus (US)-elicited afferent sensory and pain information respectively (Fanselow and LeDoux, 1999; Yang and Lu, 2005) . Although the involvement of the BLA in fear learning is widely accepted, the behavioural effects of centrally administered bumetanide on the acquisition of conditioned fear remain unclear.
Anxiety disorders are the most prevalent class of psychiatric conditions. A range of pharmacological agents including tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin-noradrenaline reuptake inhibitors, benzodiazepines, anticonvulsants and monoamine oxidase inhibitors are all currently used as anxiolytic agents. However, approximately 20 to 40% of patients poorly responded to all available medications (Denys and de Geus, 2005; Krystal et al., 2012) . Additionally, many of these anxiolytic agents can elicit severe side effects (Hirschfeld, 2003; Denys and de Geus, 2005; Krystal et al., 2012) . There is an urgent need for new anxiolytics, with fewer side effects and greater efficacy. The possibility of using loop diuretics as anxiolytics deserves further investigation. The present study aimed to evaluate the possible involvement of the BLA in the anxiolytic effect of bumetanide.
Methods

Animals
All animal care and experimental procedures were in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the Local Institutional Animal Care and Use Committee (IACUC) at National Taiwan Normal University. Adult male Wistar rats (purchased from the BioLasco Taiwan Co., Ltd., Taipei, Taiwan) with body weight between 250 and 350 g were used. The animals were housed in group cages of four rats each in a temperature-controlled animal room, with free access to food and water. They were maintained in a 12:12 light-dark cycle with lights on at 0700 h. Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) .
In this study, 124 rats were used, and nine of them were excluded for showing abnormal behaviour or cannula misplacement. All efforts were made to minimize the number of animals used, which was limited to the number required to produce meaningful experimental data. All behavioural experiments were performed during the light cycle. Animals used for electrophysiological recording and Western blotting were killed by cervical dislocation. They were then left for at least 5 min, to confirm cessation of heartbeat and autonomic breathing before decapitation.
Administration of bumetanide
For systemic administration, bumetanide (Sigma, St Louis, MO) was freshly prepared with 0.5% saline with 0.5 N NaOH (O'Donnell et al., 2004) and then injected i.v. 30 min prior to the training of conditioned fear. The dose chosen (15.2 mg kg -1 ) was based on our previous experiments (Lu et al., 2006 (Lu et al., , 2008 Ko et al., 2014; 15 .2 mg·is equivalent to 42μmol). For extracellular recordings, bumetanide was first dissolved in 100% DMSO to make a 10 mM stock solution and then diluted to 5 and 10 μM with artificial CSF (ACSF); composition: 117 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl 2 , 1.2 mM MgCl 2 , 25 mM NaHCO 3 , 2 mM NaH 2 PO 4 and 11 mM glucose; the pH value was maintained at 7.3-7.5 . The final concentration of DMSO was approximately 0.05-0.10% (Kilb et al., 2007) . Intra-amygdala injection was made through a 29-gauge injection cannula (model C313I, Plastic-one Products) and a Hamilton micro-syringe. The infusion speed and volume were 0.1 μL·min À1 and 0.3 μL per side respectively.
Intravenous injection protocol
The rats were restrained in a Plexiglas cage, and a warm compress was applied for 2-3 min to induce vasodilation of the lateral caudal veins. The tail was swabbed with alcohol pads, and the 25-gauge needle was slid into the vein at a direction almost parallel to the vein. The application of negative pressure allowed a small amount of blood to enter the syringe, confirming the correct location. The drug was gently injected into the vein, and the needle was removed from the vein. Pressure was applied to the puncture site with an alcohol pad until the rat stopped bleeding.
Stereotaxic surgery and drug microinjection
Sodium pentobarbital (50 mg·kg À1 , i.p.) was used for anaesthetizing the animals. Animals were placed in the stereotaxic apparatus (David Kopf instruments, Tujunga, CA, USA). Stainless steel guide cannulas (25 gauge, 12 mm) were implanted into the BLA or dorsal hippocampus (DH) bilaterally. The stereotaxic coordinates for guide cannula placement in the BLA and DH were anterior-posterior (AP) = 2.8 mm, dorsal-ventral (DV) = 9.0 mm and lateral-medial (LM) = +5.0 mm from bregma; AP = 1.7 mm, DV = À1.5 mm and LM = +1.2 mm from bregma respectively (Paxinos and Watson, 1997) . Three steel screws and dental cement were used to anchor the guide cannulas. To prevent the cannula from clogging, stainless steel wires were inserted into each cannula. Penicillin (100 000 IU·kg
À1
) was i.m. injected once a day for a total of 3 days to reduce the risk of infection (Corrigall et al., 1992) . The animals were allowed to recover for 7 days prior to the behavioural experiments.
Fear-potentiated startle
Rats were trained and tested in a commercialized startle system (San Diego Instruments, San Diego, CA, USA), and the startle responses were measured according to the displacement of an accelerometer beneath the startle chamber. Startle amplitude was defined as the peak response within 200 ms after CS onset. The behavioural procedures contained an acclimation phase, a baseline startle test phase, a fearconditioning phase and a fear-potentiated startle (FPS) test, which are summarized below.
Acclimation. Acclimation was performed in three consecutive days, and animals were placed in the startle chambers for 10 min and then returned to their home cages. Neither CS nor US was given to the animals.
Baseline startle test. On the next two consecutive days following the acclimation phase, the animals were placed in the startle chambers. Thirty 95 dB startle stimuli with a 30 s inter-stimulus interval (ISI) were presented. Those animals which showed less than 15% startle response, relative to the mean baseline of all animals, were excluded from the study.
Fear conditioning. The rats were subjected to the fear conditioning 24 h later. They received 10 light foot-shock pairings. The US (foot shock) was delivered during the last 0.5 s of the 3.7 s CS presentation (light). The average intertrial interval was 4 min (range =3-5 min), and the shock intensity was 0.6 mA. Bumetanide was injected i.v. 30 min prior to the fear conditioning. The jumping response induced by foot shock (shock activity) was recorded.
Fear-potentiated startle test. The rats were returned to the startle chambers 24 h later and allowed to adapt for 5 min, and they were then presented with 30 startle-eliciting noise bursts (95 dB, 30 s ISI) for obtaining a stable baseline, prior to the following light-noise test trials. A total of 60 startleeliciting noise bursts were presented. Thirty of them were in darkness (noise alone), and 30 of them were presented 3.2 s after the onset of the 3.7 s light (light noise). Those startleeliciting noise bursts were presented in a balanced, irregular order with a 30 s ISI, on average.
Monitoring of locomotor activity
The behaviour chamber is a cubic chamber with 48 cm each side. The animal's horizontal activity and stereotypic behaviours were monitored and recorded by a commercial monitoring system (Noldus Information Technology, Wageningen, The Netherlands). The locomotor activity monitoring was performed immediately after the FPS test, and the monitoring lasted for 5 min.
Extracellular recordings from brain slices
Coronal slices of rat brain (400 μm thick) were prepared with a vibratome (MA752; Sigma, Campden Instruments Ltd, Loughborough, Leics, UK). Slices were placed in oxygenated ACSF for at least 1 h in room temperature for stabilization before recording. Each slice was then transferred to the recording chamber where it was held submerged between two nylon nets and maintained at 32 ± 1°C. The ACSF was perfused constantly at a rate of 3-4 mL·min À1 . A bipolar stimulating electrode (SNE-2OOX; David Kopf Instruments) was placed into the visible cell layer representing layer II/III neurons in the BLA. Field EPSPs (fEPSPs) were recorded extracellularly using glass microelectrodes filled with 3 M NaCl (3-8 MΩ). The evoked fEPSP signals were recorded by an Axoclamp-2B amplifier (Axon Instruments, Union City, CA, USA). The responses were low square-wave pulses 200 ms in duration that were delivered at 20 s intervals, filtered at 1 kHz and digitized at 5 kHz (Digidata 1322A; Axon Instruments). The stimulation voltage was adjusted individually for producing an fEPSP that was 30-40% of the maximal response that could be evoked. The strength of synaptic transmission was quantified by measuring the initial slope of the fEPSP and analysed using pCLAMP software (version 10.2; Axon Instruments). Input-output (I/O) relationships and paired-pulse facilitation (PPF) were assessed to measure basal synaptic transmission and presynaptic plasticity. I/O curves were obtained from eight incremental stimulation intensities (40-60 mV). Long-term potentiation (LTP) was induced by high-frequency stimulation (HFS) at an intensity twice that of the test pulse. The HFS consisted of two 1 s trains of 100 Hz stimuli separated by an inter-train interval of 20 s.
Western blot analysis
The animals were killed by cervical dislocation 1 h after the training session. Animals were then decapitated, and the amygdala was collected and sonicated briefly in ice-cold homogenization buffer. Protein concentrations were measured using a Bradford assay, with BSA as the standard. Equivalent amounts of protein for each sample were resolved in 10% SDS-PAGE gels and electrophoretically transferred into PVDF membranes and blocked overnight in 5% skim milk (Cell Signaling Technology, Inc., Danvers, MA, USA). The blots were incubated with anti-phospho-ERK (New England Biolabs, Hitchin, UK) and anti-ERK antibodies (BD Biosciences, San Jose, CA, USA). Band detection was performed with Western blotting analysis system (RPN 2108; Amersham International, Amersham, UK) (Yang and Lu, 2005; Ko et al., 2014) .
Data and statistical analysis
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . The data from the FPS assays were expressed as the mean ± SEM and the mean startle amplitude was analysed by ANOVA. Between-group comparisons were also made using two-tailed t-tests for independent samples. Statistical analysis of the LTP and PPF experiments was performed using the Mann-Whitney Utest. ERK phosphorylation levels assessed via Western blot were analysed using an unpaired Student's t-test. The criterion for significance for all the comparisons was P < 0.05. All statistical analyses were performed using SPSS version 12.0 (SPSS, Chicago, IL, USA).
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/ BPS Guide to PHARMACOLOGY (Harding et al., 2018) , and are permanently archived in the Concise Guide to PHARMA-COLOGY 2017/18 (Alexander et al., 2017a,b,c) .
Results
Experiment 1: intravenous injection of bumetanide blocked the acquisition of fear-potentiated startle
To confirm the previous finding of Krystal et al. (2012) that systemic administration of bumetanide blocked conditioned fear, 16 rats were randomly assigned to control group and bumetanide-treated group based on their startle amplitude in the basal startle test. Vehicle (control group) or bumetanide (15.2 mg·kg À1 , i.v.) was injected 30 min prior to fear conditioning ( Figure 1A ). The dose chosen was based on our previous studies (Lu et al., 2006 (Lu et al., , 2008 Ko et al., 2014) . The results showed that bumetanide treatment blocked the acquisition of FPS [t(1, 14) = 2.419] ( Figure 1B) . No significant differences were observed in shock activity during the fear conditioning [t(1, 14) = À0.151] ( Figure 1C ) and locomotor activity ( Figure 1D ) immediately after the FPS test phase [t(1, 14) = À1.061].
Experiment 2: intravenous injection of bumetanide suppressed phosphorylation of ERK in the amygdala, induced by fear-conditioning
The glutamate NMDA receptor and ERK signalling cascade in the amygdala play an important role in the acquisition of FPS (Gewirtz and Davis, 1997; Yang and Lu, 2005) . To study the possible involvement of the ERK signalling pathway in the inhibition of FPS by bumetanide, we evaluated ERK phosphorylation levels in the amygdala after fear conditioning, by Western blotting. In brief, 18 animals were randomly assigned to three groups, including a naïve control group, vehicle-treated group (control) and bumetanide-treated group. The vehicle-treated and bumetanide-treated groups received a single training session of FPS. The animals were killed 1 h after the training session. The phosphorylation of ERK in the amygdala, in vehicle-treated group was significantly elevated after fear conditioning, compared with the control group [t(1, 10) = 5.463] (Figure 2A, lanes 1 and 2) . This ERK phosphorylation was significantly reduced after bumetanide treatment [t(1, 10) = 6.856] (Figure 2A, lanes  2 and 3) . The results of experiment 2 are summarized in Figure 2B . These results support our assumption that ERKs in the amygdala were involved in effects of bumetanide on FPS.
Experiment 3: administration of bumetanide suppressed high-frequency stimulation-induced LTP in the amygdala in a dose-dependent manner
Our results showed that bumetanide blocked the acquisition of conditioned fear. The acute effect of bumetanide on HFS-induced LTP formation in the amygdala was evaluated by extracellular recording. Vehicle or different doses of bumetanide were applied 10 min prior to the HFS and sustained for 10 min after the stimulation. The results showed that suprafusion of 10 μM bumetanide blocked LTP formation, compared with the 5 μM bumetanide and vehicle groups (vehicle group: 217 ± 14%; 5 μM bumetanide group: 145 ± 12% and 10 μM bumetanide group: 101 ± 4%), n = 6 for each group ( Figure 3A ). In addition, there was no significant difference between the animals in the vehicle group and the bumetanide-treated animals in terms of the I/O curve, indicating that basic synaptic density and function were not affected by the bumetanide (Figure 3B, left) . Thus, the results obtained here would not be confounded by gross differences in synaptic organization or baseline function. In addition, no significant differences in the PPF ratio were found among groups (data not shown), suggesting that a presynaptic mechanism is also not involved in the bumetanide-mediated blockade of LTP formation in the amygdala.
Experiment 4: intracranial injection of bumetanide blocked the acquisition of fear-potentiated startle
The results of experiment 1 demonstrated that i.v. injection of bumetanide disrupted the acquisition of FPS. We then assessed the role of the amygdala in the suppressive effect of bumetanide. The experimental procedure was summarized in Figure 4A . Initially, 20 BLA-cannulated rats were used, and five rats were excluded due to occlusion or misplacement. The rats were then randomly assigned to two groups: the vehicle-treated group (infused with ACSF, n = 7) or the bumetanide-treated group (n = 8) ( Figure 4B ). Vehicle or bumetanide was intracranially infused into the BLA 15 min before the fear conditioning. The animals were then tested for FPS 24 h later in the absence of drugs. The results showed that bumetanide blocked the acquisition of FPS compared with the vehicle group [t(1, 13) = 2.141] ( Figure 4C ). No significant differences in either shock activity or locomotor activity was found among groups (data not shown). Campeau and Davis (1995) reported that lesions of the BLA blocked the expression of FPS. Thus, the blockade of acquisition observed during the testing stage could result from a toxic action of bumetanide rather than from an acute suppression effect on acquisition. To test for toxicity, all animals were retrained and retested for FPS, 24 h later in the absence of drugs. The result demonstrated that the animals of bumetanide-treated group showed significant FPS in the retest, compared with the initial FPS test (Figure 4C, D) [t(7) = 3.041]. Thus, the inhibitory effect of bumetanide on FPS appeared to result from an acute drug effect rather than from any long lasting lesion caused by bumetanide.
Experiment 5: intra-amygdala infusion of bumetanide blocked the expression of conditioned fear
Our experiments had shown that bumetanide blocked the acquisition of FPS. Because the bumetanide was injected 15 min before the fear conditioning, it could affect both acquisition and/or consolidation of FPS. In addition, it is possible that bumetanide has non-specific effects that block acoustic startle response, which could be misinterpreted as a blockage effect on the acquisition of FPS. Additional fearconditioned rats were used to exclude this possibility. Thirtytwo animals were randomly assigned to two different sets (A and B), each of which was composed of two groups (n = 8 per group). In set A, the animals received vehicle (control group) or bumetanide (bumetanide-treated group) immediately after fear conditioning to test for a possible effect of bumetanide on consolidation. In set B, the animals were subjected to intra-amygdala infusion of vehicle or bumetanide 15 min prior to the testing session ( Figure 5A ). The results showed that the intra-amygdala infusion of bumetanide immediately after fear conditioning showed a trend towards reducing FPS but did not reach statistical significance [t(1, 14) = À0.217]. Compared with the control group, pre-test intra-amygdala administration significantly blocked the expression of FPS [t(1, 14) = 4.531] ( Figure 5C ). These results suggested that the blockade by bumetanide of the FPS was unlikely to be due to a non-specific effect of bumetanide on consolidation.
Experiment 6: intra-hippocampal infusion of bumetanide did not have any effects on the acquisition of conditioned fear
The previous studies showed that systemic bumetanide blocked contextual fear conditioning and FPS. We then wanted to examine whether intra-hippocampal bumetanide affected FPS. To test the possible involvement of the hippocampus, initially, 17 cannulated rats were used, one is excluded due to occlusion. Animals were randomly assigned to two groups including vehicle group (control)
Figure 3
Suprafusion of bumetanide blocked the formation of LTP in the BLA, in a dose-dependent manner. (A) From left to right, superimposed traces of fEPSPs recorded extracellularly under control conditions and after exposure to 0, 5 and 10 μM bumetanide (upper). A dose-dependent effect of bumetanide on the amygdaloid LTP formation was found (lower). (B) The I/O curve. The fEPSP slopes were comparable between the vehicletreated and bumetanide-treated slices over a given range of stimulus intensities. No significant differences were found. The fibre volley amplitudes were similar between the vehicle-treated and bumetanide-treated slices over a given range of stimulus intensities. Each vertical bar represents the mean ± SEM for each group (n = 6). and bumetanide. Vehicle or bumetanide was infused into the DH immediately after fear conditioning. Animals were subjected to FPS testing 24 h later in the absence of drugs. The results showed that intra-hippocampal infusion of bumetanide did not have any effects on the acquisition of conditioned fear, compared with the control group [t(1, 14) = À1.137] ( Figure 6B ). These results indicated the inhibitory effect of bumetanide on the acquisition of FPS did not involve the DH. The same animals used in experiment 5 were retrained, and 24 h later, the animals were tested for FPS (retrained startle test). The animals that had been previously injected with bumetanide showed significant FPS during the retrained startle test. Data shown are means ± SEM. *P < 0.05, significantly different from the vehicle group.
Figure 5
Intra-amygdala infusion of bumetanide blocked the expression of conditioned fear. (A) Timeline of the behavioural procedures for experiment 5. The animals in set A and set B were used to test the possible effect of bumetanide on the consolidation and expression of conditioned fear respectively. (B) Absolute FPS measured 24 h after fear conditioning. Vehicle or bumetanide was infused into the amygdala, immediately after fear conditioning. (C) Vehicle or bumetanide was infused into the amygdala, 15 min before testing. The difference between the noise-alone (NA) and the light-noise (LN) trials is taken as the FPS. Data shown are means ± SEM; n = 8 per group. *P < 0.05, significantly different from the vehicle-treated group.
Discussion
Our results were consistent with previous results that acute administration of bumetanide blocked the acquisition of FPS in rodents (experiment 1). Moreover, we showed that the BLA plays an important role in inhibitory effect of bumetanide. The possibility of a non-specific effect of bumetanide on the basal startle response or shock activity was excluded. We also used Western blot and in vitro extracellular recording to further determine the possible mechanism. In addition, our results demonstrated that the phosphorylation level of ERKs in the amygdala was decreased after bumetanide administration (experiment 2). Finally, the magnitude of HFS-induced LTP in the amygdala was suppressed dosedependently after suprafusion with bumetanide. Those results are similar to our previous findings of the effects of bumetanide on hippocampal functions (Ko et al., 2014) . Taken together, these results suggest that the BLA plays a critical role on the anxiolytic effect of bumetanide. Krystal et al. (2012) reported that two diuretics, bumetanide and furosemide, exhibit anxiolytic effects in rat models of conditioned fear. They found that administration of bumetanide or furosemide significantly reduced both cue and contextual fear conditioning. Recently, we have shown that the administration of bumetanide significantly attenuated both HFS-induced hippocampal LTP formation and inhibitory avoidance learning in rats (Ko et al., 2014) . Collectively, these results suggest that the CCC system may be involved in the regulation of anxiety and make it an important target for the development of novel anxiolytics. Its clinical significance for treating anxiety disorders deserves further investigation.
In the present study, we used a lower dose of bumetanide, compared with the earlier work by Krystal et al. (2012) . The dose of bumetanide chosen was based on our previous studies (Lu et al., 2006 (Lu et al., , 2008 . We observed non-specific effects including decreased basal startle response and decreased locomotor activity, after a dose of 50 or 70 mg·kg
À1
. Therefore, we used 15.2-mg·kg À1 for subsequent experiments. We suggested that a strain difference (Long-Evans vs. Wistar rats) may account for the different dose we applied in this study. Bumetanide has been shown to affect NKCCs and KCCs with different potencies (Gagnon et al., 2007) . It should be noted that KCC2 is also expressed in human CNS and that the dose chosen in this study (40 μM) is about 1/16 of the IC 50 on KCC2 (Delpire et al., 2009) . Therefore, we suggest that the effect observed here may be due to action only on NKCCs in the brain. The permeation of bumetanide through the BBB has been recently demonstrated (Töllner et al., 2014; Donovan et al., 2015) , as bumetanide exhibited anticonvulsant effects in both animal and human studies, suggesting that bumetanide was able to cross the BBB adequately (Sullivan et al., 1996; Lopez-Samblas et al., 1997; Wang and Kriegstein, 2011) . In the present study, in which we used foot shock as the US in the FPS paradigm, it is possible that the nociceptive stimulus or the fear conditioning itself may change BBB function and result in an increase in bumetanide entering the CNS. Due to the poor BBB penetration and rapid metabolism of bumetanide in rodents, the possibility of nociception itself changing BBB function and increasing penetration of bumetanide into the brain, remains to be assessed.
According to our results, we cannot exclude the possibility that the acute effects of bumetanide on FPS occurred via a secondary effect of bumetanide on metabolic, hormonal, cardiovascular, respiratory or other system-level mechanisms that are indirectly linked to the neuronal network. Because suprafusion of bumetanide in the brain slices significantly suppressed LTP formation, it is unlikely that the acute effect occurs via a metabolite or secondary effect of bumetanide. In addition, the inhibitory effect of the i.v. injection of bumetanide on FPS could be reproduced, using an intra-amygdala infusion, providing additional evidence in support of our hypothesis.
One major question derived from our results was related to the mechanism by which the inhibition of NKCC1 attenuated the phosphorylation of ERK in the amygdala. Our previous studies demonstrated that NKCC1 blockade attenuated traumatic brain injury-induced neuronal damage and brain oedema via decreasing the phosphorylation of the Raf/MEK/ERK pathway (Lu et al., 2008; Ko et al., 2014) . In neurons, phosphorylation of ERKs can be elevated by the activation of glutamate NMDA receptors (Atkins et al., 1998; Grewal et al., 1998) and results in calcium influx (Chetkovich et al., 1991; Chen et al., 1998) . Therefore, bumetanide could reduce the activation of glutamate NMDA receptors in the amygdala after fear conditioning and affect the subsequent signal transduction pathway via a direct effect on the
Figure 6
Effects of intra-hippocampal administration of bumetanide on the acquisition of the startle response. (A) Timeline of the behavioural procedures for experiment 6. (B) Absolute FPS measured 24 h after fear conditioning. Vehicle or bumetanide was infused into the dorsal hippocampus, 15 min before fear conditioning. The difference between the noise-alone (NA) and the light-noise (LN) trials is taken as the FPS. Data shown are means ± SEM; n = 8 per group. receptors or via a reduction in glutamate release (Su et al., 2002a,b) . Another possibility is that the administration of bumetanide not only increased the chloride gradients across the membrane of neurons but also increased the magnitude of hyperpolarization after chloride channel opening, following activation of GABA A receptors (Dzhala et al., 2005; Blaesse et al., 2009) , which is similar to the anxiolytic effect of benzodiazepines through enhancing the influx of chloride via activating the GABA A receptor (Ravindran and Stein, 2010) . However, the blocking of CCCs with loop diuretics also affected intracellular ion concentrations and cell volume, both of which can significantly influence the synchronization of neuronal firing (Schwartzkroin et al., 1998; Schwartzkroin, 2000: Haglund and Hochman, 2005; Ko et al., 2014) . We would like to mention that we simply infused bumetanide into the BLA and DH. We cannot exclude the possibility that other brain regions such as the medial prefrontal cortex (mPFC) may also be involved in the inhibitory effect of bumetanide on FPS. Additional experiments such as intracranial injection of bumetanide into the mPFC will be required to test this possibility.
In conclusion, we suggest that the acute effect of systemic administration of bumetanide on FPS may be mediated by a central effect on the BLA rather than effects on peripheral target(s).
